Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 113.07 Delayed Data As of Jan 27 |  -0.61 / -0.54%Today’s Change | 102.01 Today|||52-Week Range 219.75 | -26.80% Year-to-Date |
Latest LGND News | Press Releases
| Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA Jan 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 113.68 |
| Today’s open | 117.90 |
| Day’s range | 112.61 - 116.21 |
| Volume | 8,592 |
| Average volume (3 months) | 126,619 |
| Market cap | $1.9B |
Data as of 3:59pm ET, 01/27/2022
Growth & Valuation
| Earnings growth (last year) | -100.56% |
| Earnings growth (this year) | +31.65% |
| Earnings growth (next 5 years) | +22.50% |
| Revenue growth (last year) | +54.98% |
| P/E ratio | 28.3 |
| Price/Sales | 8.63 |
| Price/Book | 2.60 |
Competitors
| ---- | ||
| CORTCorcept Therapeutics... | -0.61 | -3.55% |
| OPKOPKO Health Inc | -0.04 | -1.37% |
| TGTXTG Therapeutics Inc | -5.65 | -40.65% |
Data as of 4:24pm ET, 01/27/2022
Financials
| Next reporting date | February 10, 2022 |
| EPS forecast (this quarter) | $1.37 |
| Annual revenue (last year) | $186.4M |
| Annual profit (last year) | -$3.0M |
| Net profit margin | -1.60% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
